With the support of the wider Quest Diagnostics infrastructure, collaborate with our specialized oncology teams. They're adept at both therapeutic and diagnostic development, all centered around a key goal: ensuring patients can access your essential therapy.
As a unique global R&D entity supporting preclinical discovery to diagnostic commercialization, our goal is to help you reach your milestones more efficiently. We prioritize seamless transitions, conserving insights and understanding as you progress through each phase.
Enhance your oncology strategy to resonate more meaningfully with the global community affected by cancer.
With access to over 60 billion lab test results, an expanding range of more than 3,500 assays, and a database encompassing approximately half of the US population, we are poised to provide you with the insights necessary for data-informed decision-making at pivotal development junctures.
Tap into our vast commercialization know-how, bolstered by our versatile team. We present a rich portfolio alongside tailored partnership solutions:
This 523-gene test helps oncologists deliver precision medicine by providing personalized genomic analysis of a patient’s tumor. The expanded panel offers the opportunity for a broader scope of genomic information. For example, it may be useful for patients with limited or ill-defined treatment options and for those considering clinical trials. The addition of tumor mutation burden (TMB) and microsatellite instability (MSI) also enable simultaneous assessment of eligibility for immune checkpoint inhibitors. Tumor profiling with next-generation sequencing allows evaluation of many genomic biomarkers simultaneously.
Genes covered
523 (see complete list of genes included)
Analysis
cfDNA
Turnaround time
14 days after receipt of sample in the laboratory for prospective analysis
The escalating global challenge of oncology care demands new approaches to detection, diagnosis, and treatment.
Dive into the transformative world of healthcare with "Pathology in the era of precision medicine," a whitepaper that brings to light the evolving role of pathology in the age of personalized treatment.
Contact our pharma solutions experts to design a custom program to accommodate the needs of your study.
Connect with our team of experts today.
Expertise
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.
